{"id":"NCT01115569","sponsor":"Zogenix, Inc.","briefTitle":"Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain","officialTitle":"A Long-Term Open-Label Safety Study of Hydrocodone Bitartrate Controlled-Release Capsules With Flexible Dosing to Treat Subjects With Moderate to Severe Chronic Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05","primaryCompletion":"2012-01","completion":"2012-01","firstPosted":"2010-05-04","resultsPosted":"2014-04-25","lastUpdate":"2022-11-09"},"enrollment":424,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Pain"],"interventions":[{"type":"DRUG","name":"Hydrocodone Bitartrate","otherNames":["Hydrocodone Bitartrate Controlled Release (HC-CR)"]}],"arms":[{"label":"Hydrocodone Bitartrate","type":"EXPERIMENTAL"}],"summary":"This Phase 3, multi-center study will evaluate the long-term safety and tolerability of hydrocodone bitartrate controlled release capsule (HC-CR) at daily doses of 40 mg or more in subjects with moderate to severe chronic pain. Long-term maintenance of HC-CR efficacy will be evaluated.","primaryOutcome":{"measure":"Mean Change in Average Daily Pain","timeFrame":"1 year","effectByArm":[{"arm":"Open-label Hydrocodone Bitartrate Extended Release Capsules","deltaMin":0.921,"sd":2.2}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":50,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":638},"commonTop":["Constipation","Nausea","Headache","Somnolence","Vomiting"]}}